Assessing adherence to guideline-based DOAC prescribing in patients with atrial fibrillation: a primary care evaluation

View at publisher Summarise with VIRAT
Authors: Yusur Al-Hilali, J D Durham
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Introduction Atrial fibrillation is the most common cardiac arrhythmia in the UK and is a major risk factor for stroke. To prevent this, NICE guidelines recommend prescribing direct oral anticoagulants (DOACs) according to clinical parameters such as the CHA2DS2-VASc score. This study evaluated whether patients with AF in a UK primary care setting were prescribed these in accordance with guidelines and explored the associated clinical and financial implications. Methods A retrospective review was conducted of 184 patients, aged 75-85 years with AF, receiving a DOAC for at least 3 months. Anonymised patient data were analysed, including relevant clinical parameters, then their dosages were compared with NICE recommendations to assess adherence. A financial analysis using British National Formulary (BNF) pricing was performed to estimate potential annual savings from standardising to the most cost effective generic DOAC. Results Overall, 91% were prescribed the correct dosage, while 9% were incorrectly dosed. Of those incorrectly dosed, 71% were aged ≥80 years. Underdosing was the most frequent prescribing error. Among underdosed patients, 80% of patients had a CHA2DS2-VASc score of ≥5, indicating high thromboembolic risk. Standardising to a single generic DOAC was projected to save approximately £132,500 annually. Conclusion A notable proportion of patients were prescribed suboptimal DOAC doses, highlighting the clinical need for review. Recommendations include targeted staff training, use of visual prescribing aids, and standardisation to the most cost-effective DOAC may improve both clinical safety and cost efficiency. A follow-up evaluation is planned for early 2026 to assess improvement.

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Pharmaceutical Practices and Patient Outcomes Patient Safety and Medication Errors

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN